Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol

A. Bongiovanni, C. Liverani, S. Pusceddu, S. Leo, G. Di Meglio, S. Tamberi, D. Santini, F. Gelsomino, F. Pucci, R. Berardi, I. Lolli, F. Bergamo, S. Ricci, F. Foca, S. Severi, T. Ibrahim

Research output: Contribution to journalArticlepeer-review

Cite this